MAB8612
Anti-Varicella-Zoster Virus Antibody, Glycoprotein I
Chemicon®, from mouse
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
About This Item
Kod UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Polecane produkty
pochodzenie biologiczne
mouse
Poziom jakości
forma przeciwciała
purified antibody
rodzaj przeciwciała
primary antibodies
klon
monoclonal
reaktywność gatunkowa
human
producent / nazwa handlowa
Chemicon®
metody
immunofluorescence: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
izotyp
IgG2b
Warunki transportu
wet ice
Specyficzność
Recognizes the VZV glycoprotein I by indirect immunofluorescence, immuno-precipitation and Western blotting.
Immunogen
Epitope: Glycoprotein I
VZV HZ strain.
Zastosowanie
Anti-Varicella-Zoster Virus Antibody, Glycoprotein I is an antibody against Varicella-Zoster Virus for use in IF, IP, WB, IH.
Indirect immunofluorescence: on unfixed cells shows both cytoplasmic and membrane pattern. Staining on fixed cells shows only cytoplasmic pattern.
Immunohistochemistry: reactive on formalin fixed tissue.
Western blot
Immunoprecipitation
Optimal working dilutions must be determined by the end user.
Immunohistochemistry: reactive on formalin fixed tissue.
Western blot
Immunoprecipitation
Optimal working dilutions must be determined by the end user.
Research Category
Infectious Diseases
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral
Infectious Diseases - Viral
Postać fizyczna
1 mg/mL in 0.02M PB with 0.25M NaCl, pH 7.6, containing 0.1% sodium azide.
Format: Purified
Przechowywanie i stabilność
Maintain at 2-8°C in undiluted aliquots for up to 12 months.
Informacje prawne
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Oświadczenie o zrzeczeniu się odpowiedzialności
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
This page may contain text that has been machine translated.
Nie możesz znaleźć właściwego produktu?
Wypróbuj nasz Narzędzie selektora produktów.
Kod klasy składowania
10 - Combustible liquids
Klasa zagrożenia wodnego (WGK)
WGK 2
Temperatura zapłonu (°F)
Not applicable
Temperatura zapłonu (°C)
Not applicable
Certyfikaty analizy (CoA)
Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Varicella-zoster virus ORF12 protein activates the phosphatidylinositol 3-kinase/Akt pathway to regulate cell cycle progression.
Liu, X; Cohen, JI
Journal of virology null
Hirobumi Saitoh et al.
Internal medicine (Tokyo, Japan), 52(15), 1727-1730 (2013-08-02)
Disseminated visceral varicella-zoster virus (VZV) infection rarely occurs in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT). To date, only a few cases of isolated VZV-induced fulminant hepatitis following allo-HSCT have been reported. We herein describe the case of a
Development of recombinant varicella-zoster viruses expressing luciferase fusion proteins for live in vivo imaging in human skin and dorsal root ganglia xenografts.
Stefan L Oliver, Leigh Zerboni, Marvin Sommer, Jaya Rajamani, Ann M Arvin et al.
Journal of Virological Methods null
Ryo Takahashi et al.
Journal of immunology (Baltimore, Md. : 1950), 192(3), 969-978 (2014-01-01)
It remains unknown why the occurrence of eczema herpeticum (EH) caused by an extensive disseminated cutaneous infection with HSV-1 or HSV-2 is associated with the exacerbation of atopic dermatitis lesions after withdrawal of treatment. Although regulatory T cells (Tregs) limit
Identification of an important immunological difference between virulent varicella-zoster virus and its avirulent vaccine: viral disruption of dendritic cell instruction.
Cindy Gutzeit,Martin J Raftery,Matthias Peiser,Karsten B Tischer,Martina Ulrich et al.
Journal of immunology (Baltimore, Md. : 1950) (1950)
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej